Xeroderma pigmentosum: Spinal cord astrocytoma with 9-year survival after radiation and isotretinoin therapy

Journal of Cutaneous Medicine and Surgery

Volumn 2, Issue 3, 1998, Pages 153-158

  DiGiovanna, John J ^a   Patronas, Nicholas ^b   Katz, David ^c,d,e   Abangan, Donita ^c,f   Kraemer, Kenneth H ^c  

^a BROWN UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e HARTFORD HOSPITAL   (United States)

^f Sutter North Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; ISOTRETINOIN;

ADULT; ARTICLE; ASTROCYTOMA; CANCER PREVENTION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DNA REPAIR; ECTROPION; HUMAN; LIGAMENT CALCINOSIS; MALE; MYELOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PYOGENIC GRANULOMA; SKIN CANCER; SKIN INFECTION; SPINAL CORD TUMOR; TIME; ULTRAVIOLET RADIATION; XERODERMA PIGMENTOSUM;

EID: 0031751372     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1177/120347549800200308     Document Type: Article

References (34)

1. Kraemer KH. Heritable diseases with increased sensitivity to cellular injury. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al. Dermatology in general medicine. 4th Ed. New York: McGraw-Hill, 1993:1974-1991.
2. Cleaver JE, Kraemer KH. Xeroderma pigmentosum and Cockayne syndrome. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 7th Ed. New York:McGraw-Hill, 1995:4393-4419.
3. Nakamura T, Ono T, Yoshimura K, et al. Malignant schwannoma associated with xeroderma pigmentosum in a patient belonging to complementation group D. J Am Acad Dermatol 1991; 25: 349-353.
4. Yamashiro S, Nagahiro S, Mimata C, et al. Malignant trigeminal schwannoma associated with xeroderma pigmentosum - case report. Neurol Med Chir (Tokyo) 1994; 34:817-820.
5. Kraemer KH, Lee M-M, Andrews AD, et al. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer: the xeroderma pigmentosum paradigm. Arch Dermatol 1994; 130: 1018-1021.
6. Kraemer KH, Lee MM, Scotto J. DNA repair protects against cutaneous and internal neoplasia: evidence from xeroderma pigmentosum. Carcinogenesis 1984; 5:511-514.
7. Kraemer KH, DiGiovanna JJ, Moshell AN, et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318:1633-1637.
8. Burger PC, Scheithauer BW, Vogel FS. Surgical pathology of the nervous system and its coverings. 3rd Ed. New York: Churchill Livingstone, 1991:196-629.
9. Nelson JS, Parisi JE, Schochet SS Jr. Principles and practice of neuropathology. St. Louis: Mosby, 1993:128.
10. Kraemer KH, DiGiovanna JJ, Peck GL. Chemoprevention of skin cancer in xeroderma pigmentosum. J Dermatol 1992; 19:715-718.
11. Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987; 123:241-250.
12. Gaspari AA, Fleisher TA, Kraemer KH. Impaired Interferon production and natural killer cell activation in patients with the skin cancer-prone disorder, xeroderma pigmentosum. J Clin Invest 1993; 92:1135-1142.
13. Ahrens C, Grewe M, Berneburg M, et al. Photocarcinogenesis and inhibition of intercellular adhesion molecule 1 expression in cells of DNA-repair-defective individuals. Proc Natl Acad Sci USA 1997; 94:6837-6841.
14. Robbins JH, Kraemer KH, Lutzner MA, et al. Xeroderma pigmentosum. An inherited disease with sun sensitivity, multiple cutaneous neoplasms, and abnormal DNA repair. Ann Intern Med 1974; 80: 221-248.
15. Reardon JT, Bessho T, Kung HC, et al. In vitro repair of oxidative DNA damage by human nucleotide excision repair system: possible explanation for neurodegeneration in xeroderma pigmentosum patients. Proc Natl Acad Sci USA 1997; 94:9463-9468.
16. Reimer R, Onofrio BM. Astrocytomas of the spinal cord in children and adolescents. J Neurosurg 1985; 63:669-675.
17. Kopelson G, Linggood RM. Intramedullary spinal cord astrocytoma versus glioblastoma: the prognostic importance of histologic grade. Cancer 1982; 50:732-735.
18. Garcia DM. Primary spinal cord tumors treated with surgery and postoperative irradiation. Int J Radiat Oncol Biol Phys 1985; 11: 1933-1939.
19. Linstadt DE, Wara WM, Leibel SA, et al. Postoperative radiotherapy of primary spinal cord tumors. Int J Radiat Oncol Biol Phys 1989; 16:1397-1403.
20. Rossitch E Jr., Zeidman SM, Burger PC, et al. Clinical and pathological analysis of spinal cord astrocytomas in children. Neurosurgery 1990; 27:193-196.
21. Sandler HM, Papadopoulos SM, Thornton AF Jr., et al. Spinal cord astrocytomas: results of therapy. Neurosurgery 1992; 30: 490-493.
22. Hulshof MC, Menten J, Dito JJ, et al. Treatment results in primary intraspinal gliomas. Radiother Oncol 1993; 29:294-300.
23. Minehan KJ, Shaw EG, Scheithauer BW, et al. Spinal cord astrocytoma: pathological and treatment considerations. J Neurosurg 1995; 83:590-595.
24. Rothwell CI, Jaspan T, Worthington BS, et at. Gadoliniumenhanced magnetic resonance imaging of spinal tumours. Br J Radiol 1989; 62:1067-1074.
25. Krueck WG, Schmiedl UP, Maravilla KR, et al. MR assessment of radiation-induced blood-brain barrier permeability changes in rat glioma model. Am J Neuroradiol 1994; 15:625-632.
26. Finlay JL, Geyer JR, Turski PA, et al. Pre-irradiation chemotherapy in children with high-grade astrocytoma: tumor response to two cycles of the '8-drugs-in-1-day' regimen. A Childrens Cancer Group study, CCG945. J Neurooncol 1994; 21:255-265.
27. Edwards MS, Wara WM, Ciricillo SF, et al. Focal brain-stem astrocytomas causing symptoms of involvement of the facial nerve nucleus: long-term survival in six pediatric cases. J Neurosurg 1994; 80:20-25.
28. Rutz HP, Little JB. Modification of radiosensitivity and recovery from X-ray damage in vitro by retinoic acid. Int J Radiat Oncol Biol Phys 1989; 16:1285-1288.
29. Sanford KK, Parshad R, Price FM, et al. Retinoid protection against x-ray-induced chromatid damage in human peripheral blood lymphocytes. J Clin Invest 1992; 90:2069-2074.
30. DiGiovanna JJ. Retinoids for the future: oncology. J Am Acad Dermatol 1992; 27:S34-S37.
31. Hong WK, Lotan R. Retinoids in oncology. New York:Marcel Dekker, 1993:338.
32. Kaba SE, Langford LA, Yung WKA, et al. Resolution of recurrent malignant ganglioglioma after treatment with cis-retinoic acid. J Neurooncol 1996; 30:55-60.
33. Yung WK, Lotan R, Lee P, et al. Modulation of growth and epidermal growth factor receptor activity by retinoic acid in human glioma cells. Cancer Res 1989; 49:1014-1019.
34. Higuchi T, Hannigan GE, Malkin D, et al. Enhancement by retinoic acid and dibutyryl cyclic adenosine 3′: 5′-monophosphate of the differentiation and gene expression of human neuroblastoma cells induced by Interferon. Cancer Res 1991; 51: 3958-3964.